TMS+DCS for Obsessive-Compulsive Disorder
This trial will help determine if D-Cyloserine, when used alongside transcranial magnetic stimulation, is an effective treatment for Obsessive Compulsive Disorder.
- Obsessive-Compulsive Disorder
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What is the patient capacity for this research trial?
"Affirmative, according to the information posted on clinicaltrials.gov this study is actively accepting participants. The trial was initially launched in November 2021 and has been updated most recently in March 2022; it's currently recruiting 81 individuals from a single medical centre."
Are individuals over the age of 65 eligible to partake in this trial?
"This medical trial is open to patients aged 18-65. For those outside of this range, there are 24 studies for persons below the age of majority and 74 for seniors over 65 years old."
To what end are Transcranial Magnetic Stimulation and Direct Current Stimulation commonly employed?
"Transcranial Magnetic Stimulation and Direct Current Stimulation are often employed to treat those who have failed conventional therapy. Additionally, TMS+DCS has been found effective for treating inadequate response to traditional therapies, tuberculosis, extrapulmonary TB (tb), as well as pulmonary tb cases."
What potential risks are associated with Transcranial Magnetic Stimulation and Direct Current Stimulation treatments?
"Due to the Phase 2 status of this trial, our team assessed that TMS+DCS has a safety score of 2. This is because there are case studies demonstrating its safety but none yet proving efficacy."
Has a combination of transcranial magnetic stimulation and direct current stimulation ever been studied before?
"Presently, there are 9 extant studies investigating the effectiveness of TMS+DCS. Of these trials, 2 have reached Phase 3. All in all 23 medical centres across America are running such clinical experiments. Notably, a substantial number of these facilities can be found near Baltimore, MD."
Who qualifies to participate in this clinical trial?
"This clinical trial is open to 81 individuals aged between 18 and 65 with a DSM-5 diagnosis of obsessive-compulsive disorder, who have failed to respond adequately to serotonin reuptake inhibitors or cognitive behavioral therapy. Additionally, YBOCS scores must be 20 or higher and participants must pass the TMS adult safety screening questionnaire. Finally, no changes in dose nor initiation of any psychotropic medication should occur 8 weeks prior to randomization."
Are there any places available in this experiment for prospective participants?
"Affirmative. The clinical trial is open for enrolment, as per the latest details on clinicaltrials.gov - it was first published on November 26th 2021 and last edited March 22nd 2022. They are hoping to find 81 individuals from 1 medical centre to take part in this experiment."